WALTHAM, Mass., March 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today a series of events related to galectin-3 and heart failure during the American College of Cardiology’s 61st Annual Scientific Session & Expo.
